Parameter | Luseo 2.5 mg (n=80) | Luseo 5 mg (n=86) | Luseo 10 mg (n=79) | Placebo (n=83) | Total (N=328) |
Age (years)* | 59.19±8.56 | 58.86±8.46 | 57.85±9.59 | 57.96±8.63 | 58.47±8.79 |
Female sex, n (%) | 46 (57.5) | 58 (67.4) | 56 (70.9) | 52 (62.7) | 212 (64.6) |
Race, n (%) | 80 (100) | 86 (100) | 79 (100) | 83 (100) | 328 (100) |
BMI (kg/m2)* | 32.13±2.87 | 30.66±3.87 | 31.54±3.20 | 31.70±3,40 | 31.49±3.39 |
BMI ≥30 kg/m2, n (%) | 62 (77.5) | 53 (61.6) | 54 (68.3) | 62 (74.7) | 231 (70.4) |
Waist circumference (cm)* | 105.51±10.76 | 102.33±12.39 | 102.70±10.60 | 103.30±11.90 | 103.44±11.48 |
HbA1c (%)* | 8.52±0.66 | 8.54±0.71 | 8.56±0.73 | 8.54±0.71 | 8.54±0.70 |
HbA1c ≥8.5%, n (%) | 27 (33.8) | 33 (38.3) | 29 (36.7) | 39 (47.0) | 128 (39.0) |
FPG (mmol/L)* | 9.15±2.17 | 9.07±2.29 | 9.28±2.01 | 9.54±2.16 | 9.26±2.16 |
eGFR >60 mL/min, n (%) | 76 (95.0) | 78 (90.7) | 69 (87.3) | 80 (96.4) | 303 (92.4) |
Diabetes duration (years)* | 5.58±5.29 | 6.48±4.89 | 6.01±4.74 | 6.24±5.36 | 6.09±5.06 |
Concomitant comorbidities | |||||
HTN, n (%) | 54 (67.5) | 55 (64.0) | 52 (65.8) | 56 (67.5) | 217 (66.2) |
Dyslipidemia, n (%) | 33 (41.2) | 34 (39.5) | 32 (40.5) | 31 (37.3) | 130 (39.6) |
W0 data are provided descriptively; no formal intergroup analysis was performed.
*Mean±SD percentages may not total 100 because of rounding.
BMI, body mass index; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HTN, arterial hypertension; luseo, luseogliflozin; W0, week 0.